AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. In Germany AbbVie is based in Wiesbaden with its country headquarter and in Ludwigshafen with a R&D and manufacturing site.


For further information on the company visit or or follow @abbvie_de on Twitter or LinkedIn.


Project Leader: Knut Biber, Ph.D. (Head of Neuroimmunology)


AstraZeneca AB

The Neuroscience group at AstraZeneca is part of the company’s Innovative Medicines and Early Development Biotech Unit.  As part of a global biopharmaceutical organisation, we focus on developing therapies for neurodegenerative diseases, including Alzheimer’s disease, neuropsychiatric disorders and chronic pain, among others.  We are based primarily in Cambridge, UK with staff also in Boston, MA, in the US.  We are a small, agile and innovative group whose in-house scientific strength is complemented by a willingness to collaborate with industry colleagues, charities and academic scientists.

Learn more: and


Project leader: Dr Damian C. Crowther (Director, R&D, Neuroscience)
Senior scientist: Dr Peter Thornton


Janssen Pharmaceutica NV

Johnson & Johnson is one of the biggest and most versatile companies in the world in the field of health care. The Pharmaceutical Group of Johnson & Johnson operates worldwide under the name of Janssen, the pharmaceutical companies of Johnson & Johnson and is now one of the most progressive pharmaceutical companies in the world. The group is a pioneer in therapeutic fields such as oncology, immunology, neurosciences, infectious diseases & vaccines, and cardiovascular & metabolic complaints.


For more information, please visit our homepage.


Project Leader: Andreas Ebneth (Scientific Director)


Eli Lilly

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Lilly has been operating in the UK since 1934 and employs approximately 2,800 people throughout the country working in sales and marketing, research and development and bio-tech manufacturing. Lilly’s research priorities are aligned with significant UK health needs including diabetes, heart disease, mental health and cancer.

To learn more about Lilly, please visit us at


Project Leader: David Collier  (Head of Neuoscience Genetics)

Eisai Co., Ltd.

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including oncology and neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai in EMEA please visit


H. Lundbeck A/S

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.


For more information, visit us at


Project Leader: Sandra Vergo (Senior Research Scientist | Neurodegeneration)


Orion Pharma

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2015 amounted to EUR 1,016 million and the company had about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.


For more information, please visit our website.


Project Leader: Sanna Janhunen, Ph.D. (Principal Research Scientist | Alliance Manager CNS)


F. Hofmann-La Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

Our scientists are leading the effort to advance the frontiers of neuroscience and develop novel diagnostics and life-changing medicines for people with nervous system disorders. We strive to harness a deep understanding of disease biology to discover innovative new therapeutic approaches and we nurture brave inventors who engineer novel molecules. We forge collaborative bonds with partners worldwide in our quest to discover and deliver transformational new medicines.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.


For more information, please visit


Project Leader: Markus Britschgi (Senior Principal Scientist | Neuroimmunology & Neurodegeneration)



Sanofi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanofi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. With a presence in more than 100 countries and industrial sites in more than 40 countries, our industrial network, know-how and teams deliver health solutions to millions of individuals with high quality and maximum safety, regardless wherever they are manufactured. More than 110,000 people at Sanofi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.


For more information, please visit our homepage.


Project Leader: Laurent Pradier (Director | Neuroscience Therapeutic Area)


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115976. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies.

Social Media

PHAGO by Twitter PHAGO by LinkedIn

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115976. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies.